CAM
CYTK icon

ClariVest Asset Management’s Cytokinetics CYTK Stock Holding History

ClariVest Asset Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-5,086
Closed -$357K – 867
2024
Q1 		$357K Buy
+5,086
New +$393K 0.04% 368
2021
Q1 		– Sell
-31,039
Closed -$645K – 750
2020
Q4 		$645K Sell
31,039
-69,706
-69% -$1.27M 0.02% 337
2020
Q3 		$2.18M Sell
100,745
-4,536
-4% -$106K 0.07% 211
2020
Q2 		$2.48M Sell
105,281
-44,772
-30% -$840K 0.07% 199
2020
Q1 		$1.77M Sell
150,053
-2,463
-2% -$31.4K 0.05% 213
2019
Q4 		$1.62M Sell
152,516
-27,846
-15% -$286K 0.04% 272
2019
Q3 		$2.05M Sell
180,362
-2,400
-1% -$30.1K 0.05% 254
2019
Q2 		$2.06M Sell
182,762
-1,700
-0.9% -$16.4K 0.05% 250
2019
Q1 		$1.49M Sell
184,462
-13,683
-7% -$101K 0.03% 357
2018
Q4 		$1.25M Buy
198,145
+76,497
+63% +$561K 0.03% 367
2018
Q3 		$1.2M Sell
121,648
-3,402
-3% -$27.3K 0.02% 393
2018
Q2 		$1.04M Buy
125,050
+41,076
+49% +$342K 0.02% 438
2018
Q1 		$604K Buy
83,974
+400
+0.5% +$3.43K 0.01% 481
2017
Q4 		$682K Sell
83,574
-5,542
-6% -$62.9K 0.01% 462
2017
Q3 		$1.29M Hold
89,116
– – 0.03% 325
2017
Q2 		$1.08M Sell
89,116
-60
-0.1% -$834 0.03% 330
2017
Q1 		$1.15M Hold
89,176
– – 0.03% 326
2016
Q4 		$1.08M Sell
89,176
-87
-0.1% -$923 0.03% 330
2016
Q3 		$820K Hold
89,263
– – 0.02% 327
2016
Q2 		$847K Buy
89,263
+12,000
+16% +$98.5K 0.03% 308
2016
Q1 		$544K Sell
77,263
-23,728
-23% -$173K 0.02% 352
2015
Q4 		$1.06M Buy
+100,991
New +$991K 0.03% 284

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

ClariVest Asset Management's CYTK Position: Q2 2024 in Review

ClariVest Asset Management sold out of Cytokinetics (CYTK) in Q2 2024, closing a stake of 5,086 shares — an estimated $357K sold.

ClariVest Asset Management first reported a position in CYTK in Q4 2015 and held it in 22 quarters. The position peaked at $2.48M in Q2 2020. 343 funds tracked by Wall St. Rank hold CYTK as of Q2 2024.

  • ClariVest Asset Management reported no remaining Cytokinetics position as of Q2 2024 after selling out during the quarter.
  • ClariVest Asset Management sold 5,086 Cytokinetics shares in Q2 2024, an estimated $357K.
  • ClariVest Asset Management first reported a position in Cytokinetics in Q4 2015 and held it in 22 quarters.
  • ClariVest Asset Management's Cytokinetics position peaked at $2.48M in Q2 2020.
  • 343 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2024.

Based on ClariVest Asset Management's 13F filing for Q2 2024, filed 7 Aug 2024.